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Menstrual disturbances  
in perimenopausal women: 
What’s best?
  
Evidence-based answer
It’s best to start with nonsteroidal anti-
inflammatory drugs (nsAIDs), which 
effectively reduce heavy menstrual bleeding 
(strength of recommendation [sOr]: B, 
systematic review of randomized clinical 
trials [rCTs]). 
 Perimenopausal women with heavy 
bleeding not controlled by nsAIDs, or other 
forms of dysfunctional uterine bleeding, 
can benefit from continuous, combined 
hormonal therapy with estrogen and 
progestin; hormonal therapy with estrogen 
and a cyclical progestin; or a cyclical 
progestin alone (sOr: B, rCTs and a 
systematic review of rCTs). Intrauterine 
devices (IuDs) containing levonorgestrel 
also effectively reduce bleeding and 
may avoid surgical intervention (sOr: B, 
systematic review of rCTs). 
 If medical management fails, 
endometrial ablation offers an effective, 
minimally invasive alternative to 
hysterectomy (sOr: B, systematic review 
of rCTs and 1 rCT). Hysterectomy should 
be considered when medical management 
or endometrial ablation fails (sOr: B, 
systematic review of rCTs and 1 rCT). 
z Evidence summary
Perimenopause encompasses the period 
of irregular menstrual cycles and flow 
that precedes menopause (absence of 
menstrual bleeding for 1 year). Meno-
pause generally occurs between 45 and 
55 years of age; the average is 51 years. 
A review of 500 perimenopausal women 
seen sequentially by a gynecology service 
found that 18% had menorrhagia (heavy 
bleeding), metrorrhagia (intermenstrual 
bleeding), or hypermenorrhea (frequent 
periods).1 
Because few studies have examined 
the treatment of abnormal menstrual 
bleeding specifically during perimeno-
pause, therapeutic approaches are based 
primarily on studies of women before 
and shortly after this stage. Once malig-
nancy and other causes of abnormal uter-
ine bleeding (pregnancy, bleeding disor-
ders, infection, thyroid disorders, uterine 
fibroids, or polyps) have been excluded, 
treatment of perimenopausal dysfunc-
tional uterine bleeding should address 
the goals of: 
• stopping acute bleeding
•  avoiding future irregular or heavy 
bleeding
•  considering future family planning 
needs
•  preventing complications (anemia, 
unnecessary therapeutic proce-
dures). 
NSAIDs reduce heavy bleeding
A Cochrane review of 16 small RCTs that 
examined the use of NSAIDs for menor-
OnlinE ExclusivE
Medical  
management with 
NSAIDs is the first 
choice for initial  
treatment  
of abnormal  
uterine bleeding.
Edward C. Chen, MD,  
and Peter G. Danis, MD
St. John’s Mercy Family  
Medicine, St. Louis, Mo
Elizabeth Tweed, MliS, 
aHiP
Denver Health Sciences Library, 
University of Colorado, Aurora
 vOl 58, nO 6 / June 2009 331c
fast track
C
l
in
iC
a
l
 I
n
q
u
Ir
Ie
s
rhagia found NSAIDs to be superior to 
placebo and comparable to other medical 
treatments such as luteal progestin, oral 
contraceptive pills, and progestin-releas-
ing intrauterine systems.2 
Hormone therapy is also effective
An RCT of 132 perimenopausal wom-
en compared 24 weeks of combina-
tion hormonal therapy (20 mcg ethinyl 
estradiol/1 mg norethindrone acetate) 
with placebo for treating climacteric 
symptoms, including abnormal uter-
ine bleeding.3 The combination therapy 
shortened the menstrual cycle (27.7 vs 
30.4 days), decreased its variability (17.5-
46.7 days vs 22.4-66 days), and lowered 
bleeding severity scores (6.9 vs 10.2). 
Hormonal therapy didn’t shorten 
bleeding episodes, however, and was as-
sociated with a higher incidence of in-
termenstrual bleeding during the first 3 
months of treatment.
Continuous, combined  
estrogen/progestogen therapy 
An RCT of 120 perimenopausal women 
with irregular menstrual cycles compared 
low-dose (1 mg) continuous estradiol 
and cyclical progestogens (10 mg dy-
drogesterone) with cyclical progestogens 
alone.4 In the combined treatment group, 
the incidence of cyclical menstrual bleed-
ing was 86%, and 76% of all cycles were 
rated normal in amount and duration 
of bleeding. In the cyclical progestogen 
group, the incidence of cyclical menstrual 
bleeding during treatment was 76%, and 
70% of all cycles were rated normal. 
A systematic review, comprised pri-
marily of RCTs, examined uterine bleed-
ing patterns in 3000 postmenopausal 
women taking combined continuous 
hormones (various regimens of estro-
gen and progestin).5 In 22 of 23 studies 
that included data past 6 months, 75% 
or more of participants became amenor-
rheic while on therapy. Irregular uterine 
bleeding before 6 months of therapy was 
common, however, and was presumed to 
lower patient compliance. 
Combined therapy avoids risk  
of endometrial hyperplasia
A more recent Cochrane review of 30 
RCTs examined hormone replacement 
therapy for irregular bleeding and endo-
metrial hyperplasia in postmenopausal 
women who had been amenorrheic for 
at least 6 months (a more liberal criterion 
for inclusion).6 The review concluded that 
many of the women treated with con-
tinuous estrogen and progestin became 
amenorrheic after 1 year of therapy. It 
also reiterated that unopposed estrogen 
increased the risk of endometrial hyper-
plasia, whereas continuous combined es-
trogen and progestogen treatment didn’t.
Continuous progestogen regimen 
has blood loss benefit
No randomized trials have compared oral 
progestogens with placebo. A Cochrane 
review examined the use of cyclical pro-
gestogens (given from 10 to 20 days per 
cycle) for heavy menstrual bleeding.7 Cy-
clical progestogens appeared comparable 
in efficacy to NSAIDs for their effect on 
duration of menstruation; no statistically 
significant difference in menstrual blood 
loss was noted. Progestogens given in 
more continuous regimens offered great-
er benefit in terms of blood loss. 
IUDs help avoid surgery,  
but can have side effects 
A Cochrane review found that progesto-
gen-releasing IUDs significantly reduce 
heavy menstrual bleeding and are more 
effective than cyclical norethisterone 
(21 days). Patients did, however, report 
greater progestogenic side effects (breast 
tenderness and intermenstrual bleeding) 
than cyclical therapy.8 
One unblinded RCT that random-
ized women scheduled for hysterectomy 
for heavy bleeding to the levonorgestrel 
intrauterine device (LNG-IUD) or their 
existing medical therapy (not further de-
scribed) found that women in the LNG-
IUD group were more likely to cancel 
surgery. 
Another RCT comparing hysterecto-
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my with the LNG-IUD found that wom-
en with the LNG-IUD reported greater 
pain. The LNG-IUD was more cost effec-
tive at 1 and 5 years, primarily because of 
reduced surgical expenses. Some patients 
or physicians may have ethical issues with 
the device’s mechanism of action. 
Uterine ablation when preserving  
fertility doesn’t matter 
A review article of currently available 
evidence on endometrial ablation for 
heavy menstrual bleeding concluded that 
both resectoscopic endometrial ablation 
(via hysteroscopy) and nonresectoscopic 
endometrial ablative technologies (radio-
frequency electrosurgical ablation, bal-
loon thermal ablation, free fluid ablation, 
cryotherapy, microwaves) significantly 
reduce menstrual blood flow.9 These min-
imally invasive techniques were an op-
tion for women who weren’t concerned 
about preserving fertility. However, 20% 
to 40% of patients who were followed 
for more than 5 years required repeat 
treatment or hysterectomy. 
Heavy bleeding and transcervical 
endometrial resection
An RCT of 187 women, average age 42 
years, compared immediate transcervical 
resection of the endometrium to medical 
management for heavy menstrual bleed-
ing.10 A 5-year follow-up was completed 
on 144 patients. The study showed tran-
scervical resection of the endometrium to 
be superior with regard to menstrual sta-
tus (less bleeding or no bleeding), patient 
satisfaction with outcomes, and health-
related quality of life as indicated on pa-
tient questionnaires.
When other options fail… 
Patients who fail medical treatment and 
minimally invasive uterine ablation may 
require hysterectomy. An RCT of 63 pre-
menopausal women (30-50 years of age) 
with abnormal uterine bleeding com-
pared hysterectomy with medical treat-
ment.11 Hysterectomy was superior with 
regard to symptom resolution and health-
related quality of life after 6 months. 
A Cochrane review of 5 RCTs that 
compared endometrial resection and 
ablation with hysterectomy for heavy 
menstrual bleeding reported a significant 
advantage for hysterectomy in symptom 
resolution and patient satisfaction.12 Al-
though the initial cost was higher for the 
hysterectomy group, the difference nar-
rowed over time because of the need for 
retreatment in the endometrial destruc-
tion group. 
Recommendations
The American College of Obstetricians 
and Gynecologists (ACOG) recommends 
initial medical management (cyclic pro-
gestins, low-dose oral contraceptives, or 
cyclic hormone replacement therapy) for 
anovulatory bleeding in women 40 years 
and older.13 
The Practice Committee of the Amer-
ican Society for Reproductive Medicine 
lists low-dose combination hormonal 
pills, progestin, progestin-containing 
IUDs, and hormone replacement therapy 
as medical treatment options.14 
ACOG notes that minimally inva-
sive surgical options such as hystero-
scopic endometrial ablation result in 
less short-term morbidity and cost less 
than hysterectomy.15 Results with re-
sectoscopic and nonresectoscopic tech-
niques are similar. Hysterectomy rates 
following these approaches are at least 
24% at 4 years.15 n
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